184 related articles for article (PubMed ID: 21403859)
1. Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.
Fournier P; Schirrmacher V
Clin Dev Immunol; 2010; 2010():423781. PubMed ID: 21403859
[TBL] [Abstract][Full Text] [Related]
2. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2010 Nov; 37(5):1203-17. PubMed ID: 20878068
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
4. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Haas C; Schirrmacher V
Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
[TBL] [Abstract][Full Text] [Related]
6. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
Schirrmacher V
Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
[TBL] [Abstract][Full Text] [Related]
8. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
[TBL] [Abstract][Full Text] [Related]
9. CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.
Willems A; Schoonooghe S; Eeckhout D; De Jaeger G; Grooten J; Mertens N
Cancer Immunol Immunother; 2005 Nov; 54(11):1059-71. PubMed ID: 15891885
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
Zhukovsky EA; Morse RJ; Maus MV
Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
[TBL] [Abstract][Full Text] [Related]
11. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
13. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
Satta A; Grazia G; Caroli F; Frigerio B; Di Nicola M; Raspagliesi F; Mezzanzanica D; Zaffaroni N; Gianni AM; Anichini A; Figini M
Front Immunol; 2019; 10():2514. PubMed ID: 31708930
[TBL] [Abstract][Full Text] [Related]
14. Immunization with virus-modified tumor cells.
Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25.
Fournier P; Aigner M; Schirrmacher V
Int J Oncol; 2010 Dec; 37(6):1439-52. PubMed ID: 21042712
[TBL] [Abstract][Full Text] [Related]
18. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
19. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
20. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
